Case Western Reserve scientists developed a new chemical compound that shows extraordinary promise in restoring function lost to spinal cord injury. The compound, which the researchers dubbed ...
Nervgen Pharma Corp. rolled out expanded findings from the Connect phase Ib/IIa study with NVG-291 in spinal cord injury patients showing that the 35-amino acid peptide derived from the intracellular ...
Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with ...
The MarketWatch News Department was not involved in the creation of this content. CHICAGO, July 16, 2025 /PRNewswire/ -- Amphix Bio, a pre-clinical stage company developing a new therapeutic modality ...
Realizing a Phase I human clinical trial commencing to test the efficacy and safety of the transplantation of olfactory cell nerve bridges to treat chronic spinal cord injury. Since the passing of ...
Vancouver, British Columbia--(Newsfile Corp. - September 30, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for ...
Please provide your email address to receive an email when new articles are posted on . There is an urgent need to enable functional recovery in people with spinal ...
As spinal cord injuries increasingly affect older adults, new research reveals a surprising pattern in recovery. The study shows that aging does not appear to slow the healing of nerves themselves, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results